Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in non-Hodgkin lymphoma patients within 6 months after treatment

The Covid-19 pandemic has caused millions of deaths worldwide. Although vaccines have been developed, patients on immunosuppressive therapy are less likely to respond. This study was aimed at investigating the efficacy of a Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Tvito, Ariella, Ronson, Aaron, Ghosheh, Renan, Kharit, Mira, Ashkenazi, Jakob, Magen, Sophie, Broide, Ellen, Benayoun, Emmanuel, Rowe, Jacob M., Ofran, Yishai, Ganzel, Chezi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc. 2022
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691955/
https://www.ncbi.nlm.nih.gov/pubmed/34952139
http://dx.doi.org/10.1016/j.exphem.2021.12.396
Descripción
Sumario:The Covid-19 pandemic has caused millions of deaths worldwide. Although vaccines have been developed, patients on immunosuppressive therapy are less likely to respond. This study was aimed at investigating the efficacy of a Covid-19 vaccine (Pfizer-BioNTech) in patients with non-Hodgkin lymphoma treated with anti-CD20 monoclonal antibodies. Only 1 of 28 lymphoma patients (3.6%) developed a seropositive response, compared with 100% (28/28) of the healthy volunteers. The low levels of CD19(+) lymphocytes among the lymphoma patients suggest that anti-CD20 treatment prevents the seropositive response to the vaccine. An additional vaccination might be indicated in these patients once B cells are repopulated.

Ejemplares similares